文献速递新发突发、热带与寄生虫病

磷霉素-哌喹作为非青蒿素联合疗法治疗无并发症恶性疟的疗效与安全性:加蓬单臂年龄递减概念验证研究

Efficacy and Safety of Fosmidomycin-Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该研究为在加蓬开展的单臂2期概念验证研究,纳入100例无并发症恶性疟原虫单感染患者,采用磷霉素-哌喹联合治疗3天并随访63天。符合方案人群第28天PCR校正的充分临床和寄生虫学应答率为83/83,即100%(95%CI 96-100)。治疗可快速清除寄生虫和发热,耐受性良好,但2例患者出现QT间期延长>500毫秒。

要点

  • 磷霉素-哌喹联合治疗无并发症恶性疟的PCR校正第28天ACPR率为100%(95%CI 96-100)。
  • 中位寄生虫清除时间为36小时(IQR 6-60),中位退热时间为12小时(IQR 6-48)。
  • 2例患者用药后出现QT间期延长>500毫秒,不良事件多为暂时性轻至中度。

核心结论

  • 磷霉素-哌喹联合治疗在无并发症恶性疟中显示出高疗效、安全且耐受性良好,尽管观察到心电图QT间期延长的暂时性变化。

研究设计与样本

  • 在加蓬开展的单臂2期概念验证研究,纳入100例初始寄生虫计数在1000至150000/µL之间的男女成人和儿童无并发症恶性疟原虫单感染患者。
  • 患者接受口服磷霉素(每日两次,每次30 mg/kg)和哌喹(每日一次,16 mg/kg)治疗3天,随访63天。
  • 主要疗效终点为符合方案人群经聚合酶链反应(PCR)校正的第28天充分临床和寄生虫学应答(ACPR)。

主要发现

  • 符合方案人群的PCR校正第28天ACPR率为83/83,即100%(95%CI 96-100)。
  • 14例患者在28天至63天期间出现无性寄生虫血症,经PCR分型均为新感染。
  • 中位寄生虫清除时间为36小时(IQR 6-60),中位退热时间为12小时(IQR 6-48)。
  • 心电图评估显示2例患者在用药后出现QT间期延长>500毫秒。
  • 大多数不良事件累及胃肠道和呼吸道,为暂时性且严重程度为轻至中度。

关键数值与推荐

  • 初始寄生虫计数在1000至150000/µL之间。
  • 磷霉素给药方案为每日两次30 mg/kg,哌喹为每日一次16 mg/kg,均治疗3天。
  • 主要疗效终点为PCR校正的第28天ACPR率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fosmidomycin-piperaquine is being developed as nonartemisinin-based combination therapy to meet the challenge of emerging artemisinin resistance. METHODS: The study was a phase 2, single-arm, proof-of-concept study of the efficacy, tolerability, and safety of fosmidomycin-piperaquine for the treatment of uncomplicated Plasmodium falciparum monoinfection in Gabon. Adults and children of both sexes with initial parasite counts between 1000 and 150000/µL received oral treatment with fosmidomycin (twice daily doses of 30 mg/kg) and piperaquine (once daily dose of 16 mg/kg) for 3 days and followed-up for 63 days. The primary efficacy endpoint was the per-protocol polymerase chain reaction (PCR)-corrected day 28 adequate clinical and parasitological response (ACPR). RESULTS: One hundred patients were enrolled. The PCR-corrected day 28 ACPR rate was 83/83, or 100% (95% confidence interval, 96-100). Fourteen patients had asexual parasitaemia between day 28 and day 63; all were typed by PCR as new infections. Fosmidomycin-piperaquine therapy led to rapid parasite clearance (median, 36 hours; interquartile range [IQR], 6-60) and fever clearance time (median, 12 hours; IQR, 6-48). The electrocardiogram assessments showed 2 patients with prolonged QT interval >500 msec following study drug administration. The majority of adverse events affected the gastrointestinal and respiratory tracts and were transient and mild to moderate in severity. CONCLUSIONS: This is the first report of the use of the combination fosmidomycin-piperaquine. The combination appeared to have high efficacy and be safe and well tolerated despite observed transient changes in electrocardiogram with prolongation of the QT interval. Clinical Trials Registration. NCT02198807.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mombo-Ngoma G, Remppis J, Sievers M, et al. Efficacy and Safety of Fosmidomycin-Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon. Clin Infect Dis. 2018. PMID: 29293893. doi:10.1093/cid/cix1122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。